312 related articles for article (PubMed ID: 19222899)
1. Drug substances presented as sulfonic acid salts: overview of utility, safety and regulation.
Elder DP; Snodin DJ
J Pharm Pharmacol; 2009 Mar; 61(3):269-78. PubMed ID: 19222899
[TBL] [Abstract][Full Text] [Related]
2. The utility of sulfonate salts in drug development.
Elder DP; Delaney E; Teasdale A; Eyley S; Reif VD; Jacq K; Facchine KL; Oestrich RS; Sandra P; David F
J Pharm Sci; 2010 Jul; 99(7):2948-61. PubMed ID: 20112423
[TBL] [Abstract][Full Text] [Related]
3. Residues of genotoxic alkyl mesylates in mesylate salt drug substances: real or imaginary problems?
Snodin DJ
Regul Toxicol Pharmacol; 2006 Jun; 45(1):79-90. PubMed ID: 16564608
[TBL] [Abstract][Full Text] [Related]
4. Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs).
Elder DP; Teasdale A; Lipczynski AM
J Pharm Biomed Anal; 2008 Jan; 46(1):1-8. PubMed ID: 18053672
[TBL] [Abstract][Full Text] [Related]
5. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
Elder DP; Lipczynski AM; Teasdale A
J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
[TBL] [Abstract][Full Text] [Related]
6. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
7. A practical derivatization LC/MS approach for determination of trace level alkyl sulfonates and dialkyl sulfates genotoxic impurities in drug substances.
An J; Sun M; Bai L; Chen T; Liu DQ; Kord A
J Pharm Biomed Anal; 2008 Nov; 48(3):1006-10. PubMed ID: 18687555
[TBL] [Abstract][Full Text] [Related]
8. Safety assessment of xylene sulfonic acid, toluene sulfonic acid, and alkyl aryl sulfonate hydrotropes as used in cosmetics.
Bergfeld WF; Belsito DV; Klaassen CD; Hill R; Liebler D; Marks JG; Shank RC; Slaga TJ; Snyder PW; Andersen FA
Int J Toxicol; 2011 Dec; 30(6 Suppl):270S-83S. PubMed ID: 22247238
[TBL] [Abstract][Full Text] [Related]
9. Genotoxicity profiles of common alkyl halides and esters with alkylating activity.
Sobol Z; Engel ME; Rubitski E; Ku WW; Aubrecht J; Schiestl RH
Mutat Res; 2007 Oct; 633(2):80-94. PubMed ID: 17644026
[TBL] [Abstract][Full Text] [Related]
10. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
[TBL] [Abstract][Full Text] [Related]
11. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a sensitive method for alkyl sulfonate genotoxic impurities determination in drug substances using gas chromatography coupled to triple quadrupole mass spectrometry.
Liu Z; Fan H; Zhou Y; Qian X; Tu J; Chen B; Duan G
J Pharm Biomed Anal; 2019 May; 168():23-29. PubMed ID: 30784886
[TBL] [Abstract][Full Text] [Related]
14. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical toxicological considerations for pharmaceutical salt selection.
Thackaberry EA
Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1419-33. PubMed ID: 22950715
[TBL] [Abstract][Full Text] [Related]
16. Acid-mediated formation of trifluoromethyl sulfonates from sulfonic acids and a hypervalent iodine trifluoromethylating agent.
Koller R; Huchet Q; Battaglia P; Welch JM; Togni A
Chem Commun (Camb); 2009 Oct; (40):5993-5. PubMed ID: 19809621
[TBL] [Abstract][Full Text] [Related]
17. [Advances on genotoxic impurities of sulfonate esters in pharmaceuticals].
Liu X; Li C; Han H; Zhang W; Chen D
Se Pu; 2018 Oct; 36(10):952-961. PubMed ID: 30378353
[TBL] [Abstract][Full Text] [Related]
18. Eliminating pharmaceutical impurities: Recent advances in detection techniques.
Liu DQ; Sun M; Wu L
Curr Opin Drug Discov Devel; 2010; 13(6):748-57. PubMed ID: 21061235
[TBL] [Abstract][Full Text] [Related]
19. Direct synthesis of sulfonamides and activated sulfonate esters from sulfonic acids.
Caddick S; Wilden JD; Judd DB
J Am Chem Soc; 2004 Feb; 126(4):1024-5. PubMed ID: 14746462
[TBL] [Abstract][Full Text] [Related]
20. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
Lutz WK
Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
